Osteoclast Differentiation and Bone Remodeling Mechanisms

Bone remodelling is a dynamic and tightly regulated process in which bone‐resorbing osteoclasts and bone‐forming osteoblasts interact to maintain skeletal integrity. Osteoclast differentiation begins with haematopoietic precursors that, under the influence of macrophage colony‐stimulating factor (M‐CSF) and receptor activator of nuclear factor-κB ligand (RANKL), commit to the osteoclast lineage. Downstream signalling cascades activate transcription factors such as nuclear factor of activated T cells, cytoplasmic 1 (NFATc1), which orchestrates the expression of genes essential for cell fusion, cytoskeletal organisation and protease secretion. Mature osteoclasts polarise their cytoskeleton to form a sealing zone and ruffled border, enabling acidification and enzymatic degradation of the mineralised matrix. This resorption phase is followed by osteoblastic bone formation, ensuring structural renewal. Recent work has illuminated the interplay between metabolism and epigenetic regulation, revealing that metabolic intermediates modulate chromatin states to direct osteoclastogenesis. Targeting these pathways offers novel avenues to treat disorders of excessive bone loss, such as osteoporosis or inflammatory bone destruction, while preserving bone formation.

Research from Nature Portfolio

Recent studies have unveiled critical roles for metabolic‐epigenetic coupling in controlling osteoclast differentiation. Deletion of BRCA1-associated protein 1 (BAP1) in myeloid cells impairs osteoclast resorptive function without altering cell number, by altering mitochondrial metabolism and reactive oxygen species homeostasis. This uncouples bone degradation from osteoclast formation, suggesting that targeting deubiquitinase activity may reduce bone loss while preserving coupled formation. In parallel, transient activation of the serine synthesis pathway (SSP) has been shown to be indispensable for osteoclastogenesis. Inhibition of the rate‐limiting enzyme phosphoglycerate dehydrogenase attenuates differentiation and prevents bone loss in a postmenopausal osteoporosis model by limiting α-ketoglutarate production, thereby restricting histone demethylation at the NFATc1 locus. Together, these findings highlight therapeutic potential in modulating metabolic fluxes and epigenetic marks to fine-tune osteoclast activity.

Osteoclast Differentiation and Bone Remodeling Mechanisms publication trend

The graph below shows the total number of articles in osteoclast differentiation and bone remodeling mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Osteoclastogenesis: The process by which monocyte/macrophage precursors differentiate into multinucleated osteoclasts under M-CSF and RANKL stimulation.

RANKL: A cytokine produced by osteoblasts and stromal cells that binds RANK on precursors to initiate osteoclast differentiation.

NFATc1: A master transcription factor induced during osteoclastogenesis that drives expression of genes essential for fusion, resorption and cytoskeletal organisation.

Epigenetic‐metabolic coupling: The integration of metabolic intermediates with chromatin‐modifying enzymes to regulate gene expression during cell differentiation.

Serine synthesis pathway (SSP): A metabolic route generating serine and α-ketoglutarate, which supports histone demethylation and NFATc1 activation in osteoclast progenitors.

Deubiquitinase: An enzyme that removes ubiquitin from substrate proteins, influencing protein stability and function, as exemplified by BAP1 in osteoclasts.

Protein arginine methyltransferase 6 (PRMT6): An epigenetic enzyme that methylates histones to regulate gene accessibility and orchestrate metabolic shifts during osteoclast maturation.

References

1. BAP1 promotes osteoclast function by metabolic reprogramming. Nature Communications (2023).
2. Small-molecule amines: a big role in the regulation of bone homeostasis. Bone Research (2023).
3. The serine synthesis pathway drives osteoclast differentiation through epigenetic regulation of NFATc1 expression. Nature Metabolism (2024).
4. Unraveling the intricacies of osteoclast differentiation and maturation: insight into novel therapeutic strategies for bone-destructive diseases. Experimental & Molecular Medicine (2024).
5. PRMT6 Epigenetically Drives Metabolic Switch from Fatty Acid Oxidation toward Glycolysis and Promotes Osteoclast Differentiation During Osteoporosis. Advanced Science (2024).